ClinicalTrials.gg
WithdrawnNCT06352086Updated Oct 8, 2024

Understanding Visual Processing After Occipital Stroke

An observational study in Vision Loss Partial, Vision; Loss, Both Eyes and Hemianopia, Homonymous, sponsored by University of Rochester. Withdrawn. Open to participants aged 21 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-10-08.

Primary conditionHemianopsiaRegistry: BlindnessReclassifiedWhy we changed it
Registry
Blindness — the first condition term the registry derived for this study.
ClinicalTrials.gg
Hemianopsia
Why
  1. The study's listed conditions name Hemianopsia, a narrower term within Blindness.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by University of Rochester · Observational

Why this study was withdrawn
Study was never officially approved by IRB and never open to enrollment. Submission withdrawn due to lack of funding.
Study type
Observational
Model
Case-only
Time perspective
Cross-sectional
Enrollment
0
Ages
21 Years to 75 Years
Sex
All
01

Study summary

The purpose of this study is to investigate how visual orientation discrimination and metacognition (i.e., perceptual confidence) are affected by occipital stroke that causes hemianopia and quadrantanopia in adults. This research will provide insight as to how the residual visual system, which not directly damaged by the occipital stroke, processes orientation (assayed in terms of orientation discrimination) and metacognition (by measuring perceptual confidence for orientation discrimination). These measures will be used to refine computational models that attempt to explain how the brain copes with loss of primary visual cortex (V1) as a result of stroke. This knowledge is essential to devise more effective visual rehabilitation therapies for patients suffering from occipital strokes.

02

Conditions studied

  • Vision Loss Partial
  • Vision; Loss, Both Eyes
  • Hemianopia, Homonymous
  • Hemianopia
  • Quadrantanopia
  • Stroke, Ischemic
  • Stroke - Occipital Infarction
  • Cortical Blindness
  • Occipital Lobe Infarct
  • Peripheral Visual Field Defect of Both Eyes

Browse trials for

Keywords

  • Occipital stroke
  • Vision loss after stroke
  • Vision recovery
  • Vision restoration
  • Partial vision loss
  • vision loss
03

In context

Hemianopsia Reclassified

63 studies on the registry are indexed under Hemianopsia; 24 are open to participants now.

Browse Hemianopsia studies →

Lead sponsor

University of Rochester is the lead sponsor of 729 studies on the registry; 116 are open to participants now.

Of its 56 completed or terminated interventional studies of FDA-regulated products, 44 (79%) have results posted.

Compared within Hemianopsia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Blindness. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
21 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Subjects will all be individuals who have sustained partial vision loss after an occipital lobe stroke.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Residents of the United States or Canada
  • MRI and/or CT scans showing unilateral stroke or stroke-like damage to primary visual cortex or its immediate afferent white matter sustained 1-year or more prior to enrollment
  • Reliable visual field defects in both eyes as measured by Humphrey, Macular Integrity Assessment (MAIA), Goldmann, and/or equivalent perimetry. This deficit must be large enough to enclose a 5-deg diameter visual stimulus.
  • Ability to fixate on visual targets reliably for 1000ms (as demonstrated by visual fields, and verified in study participation)
  • Willing, able, and competent to provide
  • Cognitively able to understand and respond to written and oral instructions in English

Exclusion criteria

Exclusion Criteria:

  • Past or present ocular disease interfering with visual acuity
  • Corrected vision worse than 20/40 in either eye
  • Presence of damage to the dorsal Lateral Geniculate Nucleus
  • Diffuse, whole brain degenerative processes
  • Brain damage deemed by study staff to potentially interfere with testing ability or outcome measures
  • Documented history of traumatic brain injury
  • Documented history of drug/alcohol abuse
  • Current use neuroactive
  • Cognitive or seizure disorders
  • Subjects with one-sided attentional neglect
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-only
Time perspective
Cross-sectional
Enrollment
0 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Orientation discrimination threshold

    Assessment of Static Orientation Discrimination. For each subject, the investigators will measure the ability to correctly identify the orientation of non-moving visual stimuli that vary in degree of angle tilt to the right or left of vertical. The investigators will measure the degree of angle tilt that can be reliably detected at a 72-75% correct level of performance. Tilt difference from vertical will vary between 80° (maximum) and 0.1° (minimum) based on subject performance and an adaptive staircase that will change tilt magnitude depending on subject performance, increasing the tilt (making the task easier) for each incorrect answers and decreasing tilt (making the task harder) after a number of correct answers in a row.

    Time frame: Baseline

  2. Perceptual Confidence in Orientation Discrimination

    Assessment of Metacognition (i.e., perceptual confidence) in Orientation Discrimination. For each subject, the investigators will measure their confidence in identifying an object's tilt to the right or left of vertical. A running tally of 'response points' will be collected during the orientation testing. Points will be awarded for each response on a scale, with the highest points awarded for "correct discrimination \& high confidence", intermediate points awarded for "correct discrimination \& low confidence", followed by "incorrect discrimination \& low confidence" and with points subtracted for "incorrect discrimination \& high confidence". Total points will be recorded for each test, with the patient asked to accumulate the highest number of points they can during the task.

    Time frame: Baseline

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2025; primary completion for Sep 2028, 33 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2024
First posted
Apr 8, 2024
StartEst.
Dec 2025
Primary completionEst.
Sep 2028
CompletionEst.
Sep 2029
Last update
Oct 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06352086
Responsible party
Krystel Huxlin (James V. Aquavella Professor of Ophthalmology, Associate Chair for Research, Dept. Ophthalmology, University of Rochester) — Principal investigator
First posted
Apr 8, 2024
Start date
Dec 2025 (estimated)
Primary completion
Sep 2028 (estimated)
Completion
Sep 2029 (estimated)
Last update
Oct 8, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion